Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Fabio Galli

Showing results (31-40 of 37) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 37 results.
European Journal of Cancer (Oxford, England : 1990)|March 21, 2021
Oxaliplatin plus fluoropyrimidines as adjuvant therapy for colon cancer in older patients: A subgroup analysis from the TOSCA trialGerardo Rosati, Sara Lonardi, Fabio Galli, et al.
Scientific Reports|August 10, 2019
Sex-Related Differences in Impact on Safety of Pharmacogenetic Profile for Colon Cancer Patients Treated with FOLFOX-4 or XELOX Adjuvant ChemotherapyAnnamaria Ruzzo, Francesco Graziano, Francesca Galli, et al.
Scientific Reports|February 2, 2020
Author Correction: Sex-Related Differences in Impact on Safety of Pharmacogenetic Profile for Colon Cancer Patients Treated with FOLFOX-4 or XELOX Adjuvant ChemotherapyAnnamaria Ruzzo, Francesco Graziano, Francesca Galli, et al.
British Journal of Cancer|October 25, 2017
Dihydropyrimidine dehydrogenase pharmacogenetics for predicting fluoropyrimidine-related toxicity in the randomised, phase III adjuvant TOSCA trial in high-risk colon cancer patientsA Ruzzo, F Graziano, Fabio Galli, et al.
Scientific Reports|November 6, 2014
Genetic markers for toxicity of adjuvant oxaliplatin and fluoropyrimidines in the phase III TOSCA trial in high-risk colon cancer patientsAnnamaria Ruzzo, Francesco Graziano, Fabio Galli, et al.
Therapeutic Advances in Medical Oncology|February 4, 2020
Khorana score and thromboembolic risk in stage II-III colorectal cancer patients: a <i>post hoc</i> analysis from the adjuvant TOSCA trialSandro Barni, Gerardo Rosati, Sara Lonardi, et al.
The Oncologist|January 5, 2019
Impact of Metformin Use and Diabetic Status During Adjuvant Fluoropyrimidine-Oxaliplatin Chemotherapy on the Outcome of Patients with Resected Colon Cancer: A TOSCA Study SubanalysisClaudio Vernieri, Fabio Galli, Laura Ferrari, et al.
Pageof 4

Showing results (31-40 of 37) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 37 results.
European Journal of Cancer (Oxford, England : 1990)|March 21, 2021
Oxaliplatin plus fluoropyrimidines as adjuvant therapy for colon cancer in older patients: A subgroup analysis from the TOSCA trialGerardo Rosati, Sara Lonardi, Fabio Galli, et al.
Scientific Reports|August 10, 2019
Sex-Related Differences in Impact on Safety of Pharmacogenetic Profile for Colon Cancer Patients Treated with FOLFOX-4 or XELOX Adjuvant ChemotherapyAnnamaria Ruzzo, Francesco Graziano, Francesca Galli, et al.
Scientific Reports|February 2, 2020
Author Correction: Sex-Related Differences in Impact on Safety of Pharmacogenetic Profile for Colon Cancer Patients Treated with FOLFOX-4 or XELOX Adjuvant ChemotherapyAnnamaria Ruzzo, Francesco Graziano, Francesca Galli, et al.
British Journal of Cancer|October 25, 2017
Dihydropyrimidine dehydrogenase pharmacogenetics for predicting fluoropyrimidine-related toxicity in the randomised, phase III adjuvant TOSCA trial in high-risk colon cancer patientsA Ruzzo, F Graziano, Fabio Galli, et al.
Scientific Reports|November 6, 2014
Genetic markers for toxicity of adjuvant oxaliplatin and fluoropyrimidines in the phase III TOSCA trial in high-risk colon cancer patientsAnnamaria Ruzzo, Francesco Graziano, Fabio Galli, et al.
Therapeutic Advances in Medical Oncology|February 4, 2020
Khorana score and thromboembolic risk in stage II-III colorectal cancer patients: a <i>post hoc</i> analysis from the adjuvant TOSCA trialSandro Barni, Gerardo Rosati, Sara Lonardi, et al.
The Oncologist|January 5, 2019
Impact of Metformin Use and Diabetic Status During Adjuvant Fluoropyrimidine-Oxaliplatin Chemotherapy on the Outcome of Patients with Resected Colon Cancer: A TOSCA Study SubanalysisClaudio Vernieri, Fabio Galli, Laura Ferrari, et al.
Pageof 4